Carmustine Rapid Infusion via Propylene Glycol Diluent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Carmustine, a drug used for treating brain cancers, is poorly soluble in water and unstable in many formulations, leading to complex and time-consuming preparation procedures and potential errors, as well as adverse effects during administration due to its requirement for ethanol as a diluent.
Innovation Solution
A method for rapidly administering carmustine using a concentrated solution comprising propylene glycol and either an aqueous 0.9% sodium chloride solution or an aqueous 5% dextrose solution, allowing for intravenous infusion over less than 2 hours, thereby reducing preparation time and avoiding ethanol-related issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If carmustine is prepared using the conventional three-step dilution method with ethanol, then the drug can be administered, but the preparation process is time-consuming and prone to errors
Solution Approach 1:
The invention extracts and eliminates ethanol from the carmustine preparation process. By using propylene glycol as a substitute diluent instead of ethanol, the method simplifies the preparation procedure from three steps to two steps, reduces preparation time, and eliminates the need for complex monitoring of ethanol-related adverse effects while maintaining drug stability and efficacy
Solution Approach 2:
The invention changes the chemical parameter of the diluent from ethanol to propylene glycol. This parameter change enables faster infusion rates (up to 4 times faster than conventional methods) while maintaining drug stability, as propylene glycol provides better solubility and stability for carmustine at higher concentrations and faster administration rates
2Loss of time
If carmustine is administered rapidly, then treatment time is reduced, but conventional formulations cause pain and burning at the injection site
Solution Approach 1:
The invention changes the physical and chemical parameters of the solution by using propylene glycol as the diluent. This enables the formulation to tolerate much higher infusion rates (up to 4 mg/mL concentration infused rapidly) without causing the pain and burning sensations associated with conventional ethanol-based formulations, thus reducing infusion time from hours to minutes while maintaining patient comfort
3Ease of manufacture
If ethanol is used as a diluent, then carmustine can be reconstituted, but patients experience intoxication and adverse effects
Solution Approach 1:
The invention extracts and removes ethanol from the carmustine formulation system. By substituting propylene glycol as the diluent, the method maintains the ability to reconstitute and administer carmustine effectively while eliminating all ethanol-related adverse effects including intoxication, nausea, vomiting, and cardiovascular complications, thereby improving patient safety and tolerance
Solution Approach 2:
The invention introduces propylene glycol as an intermediary substance to replace ethanol in the carmustine formulation. Propylene glycol serves as a safe and effective mediating diluent that provides comparable or superior solubility and stability properties without the harmful side effects of ethanol, enabling safe and effective carmustine administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables a faster and more efficient administration of carmustine with reduced adverse effects, improved stability of the drug solution, and fewer opportunities for errors, allowing for outpatient treatment even at high doses without the need for increased post-infusion observation.
Implementation Method 1
carmustine may be rapidly administered in a concentrated solution comprising propylene glycol and either an aqueous 0.9% sodium chloride solution or an aqueous 5% dextrose solution
Data Source
AI summary
The present invention relates to a method for rapid infusion of carmustine, for example, in 30 minutes or 1 hour.